<DOC>
	<DOCNO>NCT00100971</DOCNO>
	<brief_summary>RATIONALE : Vaccines make person 's white blood cell cancer cell may make body build effective immune response kill cancer cell . PURPOSE : This phase I trial study side effect best dose vaccine therapy treat patient acute myeloid leukemia .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose autologous dendritic leukemic fusion cell vaccine patient acute myeloid leukemia . - Determine toxicity vaccine patient . Secondary - Determine whether cellular immunity induce vaccine patient . OUTLINE : This dose-escalation study . At time diagnosis , patient undergo tumor cell harvest . Patients also undergo bone marrow aspiration collect mononuclear cell obtain dendritic cell ( DC ) . If insufficient DCs obtain , patient undergo leukapheresis obtain sufficient number peripheral blood mononuclear cell ( PBMC ) . The PBMC treat laboratory sargramostim ( GM-CSF ) interleukin-4 5-7 day produce DC . Leukemic blast fuse DC generate dendritic/leukemic fusion cell vaccine . Patients undergo standard induction chemotherapy obtain remission , follow standard consolidation chemotherapy . After complete consolidation chemotherapy , patient receive autologous dendritic leukemic fusion cell vaccine subcutaneously every 2 week total 4 dos absence disease progression unacceptable toxicity . Cohorts 3 patient receive escalate dos autologous dendritic leukemic fusion cell vaccine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 patient experience dose-limiting toxicity . Patients follow every 3 month 5 year . PROJECTED ACCRUAL : A total 3-9 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis acute myeloid leukemia ( AML ) bone marrow biopsy Newly diagnose Must adequate dendritic cell AML blast isolate bone marrow and/or peripheral blood No clinical evidence CNS leukemia PATIENT CHARACTERISTICS : Age 18 Performance status Not specify Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No clinically significant autoimmune disease No active malignancy except nonmelanoma skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy More 3 month since prior immunotherapy Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
</DOC>